AlphaNet Coordinators

Ongoing support and guidance from an Alpha like you.

Support throughout your lifelong journey

Through a partnership with AlphaNet Inc., a not-for-profit organization serving the specific needs of Alphas, Zemaira CareZ offers the opportunity to connect to AlphaNet Coordinators who provide long-term support and guidance to help other Alphas manage Alpha-1. AlphaNet Coordinators are Alphas or family members of Alphas like you.

Your AlphaNet Coordinator will call you every month (or more or less often if you desire) to check in and provide assistance with any issues you may be experiencing, including:

  • Helping to ensure you have continued access to Zemaira.
  • Arranging transportation to medical appointments.
  • Offering emotional support.*
  • Suggesting educational opportunities available to you.

Watch as Peggy, an AlphaNet Coordinator, shares her story about diagnosis and living with Alpha-1.

To find out more about how AlphaNet and Zemaira work together to help you, call Zemaira CareZ at 1-866-ZEMAIRA (1-866-936-2472).

*Emotional support does not constitute professional guidance or psychological or therapeutic counseling. Our specialists offer experience-based, nontherapeutic advice and support in handling the difficulties of living with Alpha-1.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

Zemaira may not be suitable for everyone; for example, people with known hypersensitivity to components used to make Zemaira, those with a history of anaphylaxis or severe systemic response to A1-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to Zemaira include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because Zemaira is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

CSL Behring

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® and CareZ® are registered trademarks of CSL Behring LLC.

© 2017 CSL Behring. The product information presented on this site is intended for US residents only.
ZMR14-04-0006d 12/2014